Long noncoding RNA CASC11 promotes hepatocarcinogenesis and HCC progression through EIF4A3‐mediated E2F1 activation

Abstract

Background Growing evidences have been revealing that long noncoding RNAs are vital factors in oncogenesis and tumor development. Among them, cancer susceptibility candidate 11 (CASC11) has displayed an impressively essential role in various kinds of cancers including hepatocellular carcinoma (HCC). Nevertheless, its role and potential mechanism in HCC still remain to be fully investigated. Methods CASC11 expression level was evaluated by real‐time polymerase chain reaction, western blotting, and in situ hybridization staining in HCC patients, and its prognostic effect was analyzed. The role of CASC11 in HCC tumorigenesis and progression was investigated by cell proliferation assay, transwell assay, extracellular acidification rate, western blotting, flow cytometry, and an in vivo xenograft model. The interactions among CASC11, E2F transcription factor 1 (E2F1), and eukaryotic translation initiation factor 4A3 (EIF4A3) were explored by using quantitative reverse transcriptase polymerase chain reaction, western blotting, RNA‐binding protein immunoprecipitation assay, and chromatin immunoprecipitation assays. Results Upregulation of CASC11 was confirmed in HCC tissues and associated with poor prognosis. Loss of function assays showed inhibition of CASC11 expression suppressed HCC cells proliferation, mobility, and glucose metabolism and promoted apoptosis. E2F1 expression significantly decreased after inhibition of CASC11. Rescue experiments illustrated that E2F1 overexpression alleviated the suppression of CASC11 inhibition on HCC progression in vitro and in vivo. Mechanistically, CASC11 recruited EIF4A3 to enhance the stability of E2F1 mRNA. CASC11 and E2F1 impacted the activation of the NF‐κB signaling and PI3K/AKT/mTOR pathway and further regulated the expression PD‐L1 that is an important target of immunotherapy. In addition, we identified YY1 could modulate CASC11 expression by binding to its promoter. Conclusions Our data revealed that CASC11 promoted the progression of HCC by means of EIF4A3‐mediated E2F1 upregulation, indicating CASC11 is a promising diagnostic biomarker and therapeutic target for HCC.

Employing hypoxia characterization to predict tumour immune microenvironment, treatment sensitivity and prognosis in hepatocellular carcinoma

“…Enhancer of zeste 2 polycomb repressive complex 2 subunit ( EZH2 ) could mediate trimethylation on histone 3 lysine 27 (H3K27me3). Abnormal activation of EZH2 reshaped TIM, influencing tumour cell growth, patients’ survival, and tumour metastasis [70] , [71] , [72] , [75] . Therefore, less activated B cell/effector memory CD8 T cell infiltration and high expression of EZH2 may be the core factors in creating immunosuppressive tumour microenvironments, which may induce tumour immune escape and immunotherapy resistance.…”

HOTTIP Enhances Gemcitabine and Cisplatin Resistance Through Sponging miR-637 in Cholangiocarcinoma

“…A Western blot assay was performed as previously described ( 14 ). The cells were lysed with a RIPA strong buffer (Beyotime, China) on ice.…”

The Genetic Changes of Hepatoblastoma

“…LncRNAs, with over 200 nucleotides in length and involved in diverse gene regulation, account for a large number of ncRNAs (74). Various studies have verified that lncRNAs play a vital role in transcription processes, regulation of cellular contexts, assembly of protein, tumor suppressor dysregulation, and other crucial biological function (75)(76)(77)(78)(79)(80). LINC00673, located on chromosome 17q24.3, has been reported as an oncogene in diverse cancers (81)(82)(83).…”